Action BCRX BIOCRYST PHARMACEUTICALS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues BioCryst Pharmaceuticals, Inc.

Actions

BCRX

US09058V1035

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 07/06/2024 		Varia. 5j. Varia. 1 janv.
6,31 USD -2,02 % Graphique intraday de BioCryst Pharmaceuticals, Inc. -2,32 % +5,34 %
03/06 BioCryst Pharmaceuticals déclare que le médicament montre des signes de réduction des crises chez les patients atteints d'angio-œdème héréditaire MT
15/05 Transcript : BioCryst Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 02:20 PM

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Pharmaceuticals Says Drug Shows Evidence of Reducing Attacks Among Hereditary Angioedema Patients
BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment
Sector Update: Health Care Stocks Advance Late Wednesday Afternoon
BioCryst Pharmaceuticals Shares Rise 20% Following Disclosure of Executive Share Purchases
BioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical Immunology
BioCryst Says Orladeyo Granted Approval in Mexico
ORLADEYO® (berotralstat) Approved in Mexico
BioCryst Pharmaceuticals, Inc. Announces Federal Commission for Protection Against Health Risks in Mexico Grants Approval for Oral, Once-Daily ORLADEYO
BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO® (berotralstat)
BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO
BioCryst to Present at Upcoming Investor Conferences
BioCryst Pharmaceuticals, Freshpet rise; Luminar, Integra fall, Monday, 5/6/2024
Sector Update: Health Care Stocks Higher in Late Afternoon Trading
BioCryst Pharmaceuticals Shares Jump After Q1 Beat
BioCryst: Q1 Earnings Snapshot
BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update
Biocryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024
BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
North American Morning Briefing : Stock Futures Rise as Hopes of Rate Cut Return
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action BCRX
  4. Actualités BioCryst Pharmaceuticals, Inc.
  5. Autres langues